Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) reported positive results from a midstage clinical trial of its diabetes treatment LX4211 lifting the stock price 31 cents to close at $2.26.
FinancialContent is the trusted provider of stock market information to the media industry.
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial